利用CRISPR/Cas9系统构建人HPRT1基因定点突变细胞株
收稿日期: 2019-05-27
修回日期: 2019-06-28
网络出版日期: 2019-07-09
基金资助
国家转基因生物新品种培育重大专项编号:(2016ZX08006003-006);广东省重点领域研发计划项目资助编号:(2018B020203003)
Generation of cell strains containing point mutations in HPRT1 by CRISPR/Cas9
Received date: 2019-05-27
Revised date: 2019-06-28
Online published: 2019-07-09
Supported by
Supported by the National Transgenic Major Program No.(2016ZX08006003-006);The Key R&D Program of Guangdong Province No.(2018B020203003)
Hypoxanthine-guanine phosphoribosyltransferase1 (HPRT1)基因突变会导致次黄嘌呤和鸟嘌呤代谢异常,严重的代谢障碍被称为Lesch-Nyhan综合征,表现为智力低下,行为上出现强迫性自我毁伤,并伴随痛风或肾结石等症状。HPRT1基因具有多种突变模式,近年来对其突变谱的研究表明该基因具有一些“突变热点”。本研究选取了导致翻译提前终止的热点突变c.508C>T突变和c.151C>T突变,在HEK293T和HeLa细胞中,以单链寡核苷酸(single-stranded oligo-deoxyribonucleotides, ssODN)作为同源重组模板,利用CRISPR/Cas9技术构建了这两种突变的单克隆细胞株,发生定点突变的效率分别为16.3%和10%。进一步通过Western blot检测点突变的单克隆细胞的HPRT1蛋白表达水平,通过6-TG毒性实验检测点突变的单克隆细胞的次黄嘌呤/鸟嘌呤磷酸核糖转移酶活性,结果表明纯合突变的单细胞克隆不能正常表达HPRT1蛋白,其次黄嘌呤/鸟嘌呤磷酸核糖转移酶活性丧失;杂合突变的单细胞克隆的HPRT1蛋白表达量降低,仍具有部分次黄嘌呤/鸟嘌呤磷酸核糖转移酶活性。HPRT1基因定点突变细胞模型的建立可为今后建立其他HPRT1基因突变的细胞系或动物模型提供借鉴,为研究Lesch-Nyhan致病机制提供基础。
关键词: CRISPR/Cas9; HPRT1; 基因定点突变
张楷, 刘蔚, 刘小凤, 陈瑶生, 刘小红, 何祖勇 . 利用CRISPR/Cas9系统构建人HPRT1基因定点突变细胞株[J]. 遗传, 2019 , 41(10) : 939 -949 . DOI: 10.16288/j.yczz.19-108
Mutations in Hypoxanthine-guanine Phosphoribosyltransferase1 (HPRT1) gene can lead to metabolic disorder of hypoxanthine and guanine metabolism, and other severe symptoms such as hypophrenia, gout, and kidney stones, called the Lesch-Nyhan disease (LND). Although the mutations are widely distributed throughout the HPRT1 gene, there are some isolated hot spots. In this study, we aim to introduce two previously reported hot spots, c.508 C>T and c.151 C>T, which could lead to premature translational termination in HPRT1 gene. Through CRISPR/Cas9 mediated homology-directed repair (HDR) by using single-stranded oligo-deoxyribonucleotides (ssODN) as donor template, we obtained cell clones containing these two mutations in HEK293T or HeLa cells. Targeted mutation of c.508 C>T and c.151 C>T reached to 16.3% and 10%, respectively. We further detect HPRT1 protein levels with Western blot and enzyme activity with 6-TG in 5 different cell clones. HPRT1 protein and its enzymatic activity both was hardly detected in homozygous mutant cells, while reduced HPRT1 protein expression and enzymatic activity was detected in heterozygous mutant cells. Our study will be beneficial to those who working on generation of cell or animal models of HRPT1 mutations, and provides a basis for further investigations on the genetic mechanism of Lesch-Nyhan disease.
Key words: CRISPR/Cas9; HPRT1; site-directed mutagenesis
| [1] | Chen F, Pruett-Miller SM, Huang Y, Gjoka M, Duda K, Taunton J, Collingwood TN, Frodin M, Davis GD . High- frequency genome editing using ssDNA oligonucleotides with zinc-finger nucleases. Nat Methods, 2011,8(9):753-755. | |||
| [2] | Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, Liu O, Wang N, Lee G, Bartsevich VV, Lee YL, Guschin DY, Rupniewski I, Waite AJ, Carpenito C, Carroll RG, Orange JS, Urnov FD, Rebar EJ, Ando D, Gregory PD, Riley JL, Holmes MC, June CH . Establishment of HIV-1 resistance in CD4 + T cells by genome editing using zinc-finger nucleases . Nat Biotechnol, 2008,26(7):808-816. | |||
| [3] | Saleh-Gohari N, Helleday T . Conservative homologous recombination preferentially repairs DNA double-strand breaks in the S phase of the cell cycle in human cells. Nucleic Acids Res, 2004,32(12):3683-3688. | |||
| [4] | S?rensen CB, Krogsdam AM, Andersen MS, Kristiansen K, Bolund L, Jensen TG . Site-specific strand bias in gene correction using single-stranded oligonucleotides. J Mol Med (Berl), 2005,83(1):39-49. | |||
| [5] | Merriman TR . An update on the genetic architecture of hyperuricemia and gout. Arthritis Res Ther , 2015,17:98. | |||
| [6] | Merriman TR, Dalbeth N . The genetic basis of hyperuricaemia and gout. Joint Bone Spine, 2011,78(1):35-40. | |||
| [7] | Vitart V, Rudan I, Hayward C, Gray NK, Floyd J, Palmer CN, Knott SA, Kolcic I, Polasek O, Graessler J, Wilson JF, Marinaki A, Riches PL, Shu X, Janicijevic B, Smolej- Narancic N, Gorgoni B, Morgan J, Campbell S, Biloglav Z, Barac-Lauc L, Pericic M, Klaric IM, Zgaga L, Skaric-Juric T, Wild SH, Richardson WA, Hohenstein P, Kimber CH, Tenesa A, Donnelly LA, Fairbanks LD, Aringer M, McKeigue PM, Ralston SH, Morris AD, Rudan P, Hastie ND, Campbell H, Wright AF . SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet, 2008,40(4):437-442. | |||
| [8] | Visser JE, B?r PR, Jinnah HA . Lesch-Nyhan disease and the basal ganglia. Brain Res Rev, 2000,32(2-3):449-475. | |||
| [9] | Jinnah HA, De Gregorio L, Harris JC, Nyhan WL, O'Neill JP. The spectrum of inherited mutations causing HPRT deficiency: 75 new cases and a review of 196 previously reported cases. Mutat Res, 2000,463(3):309-326. | |||
| [10] | Boone M, Lin YC, Meuris L, Lemmens I, Van Roy N, Soete A, Reumers J, Moisse M, Plaisance S, Drmanac R, Chen J, Speleman F, Lambrechts D, Van de Peer Y, Tavernier J, Callewaert N . Genome dynamics of the human embryonic kidney 293 lineage in response to cell biology manipulations. Nat Commun, 2014,5:4767. | |||
| [11] | He Z, Proudfoot C, Whitelaw CB, Lillico SG . Comparison of CRISPR/Cas9 and TALENs on editing an integrated EGFP gene in the genome of HEK293FT cells. Springer Plus, 2016,5(1):814. | |||
| [12] | Holbrook JA, Neu-Yilik G, Hentze MW, Kulozik AE . Nonsense-mediated decay approaches the clinic. Nat Genet, 2004,36(8):801-
/
|